Anti-CTLA-8 / IL-17a Reference Antibody (vunakizumab)
- Product Code: 139984
Molecular Weight: | Molecular Formula: | ||
---|---|---|---|
EC Number: | MDL Number: | ||
Melting Point: | Boiling Point: | ||
Density: | Storage Condition: | -20℃ |
Product Description:
Used in the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by neutralizing interleukin-17A (IL-17A), a key cytokine involved in inflammatory pathways, thereby reducing inflammation and disease symptoms. This antibody helps decrease skin lesions in moderate to severe plaque psoriasis and improves joint function and quality of life in patients with chronic inflammatory conditions. It is administered via subcutaneous injection and is part of a class of biologic therapies targeting specific components of the immune system.
Sizes / Availability / Pricing:
Size | Availability | Price | Quantity |
---|---|---|---|
50μg | 10-20 days | ฿4,980.00 |
+
-
|
Anti-CTLA-8 / IL-17a Reference Antibody (vunakizumab)
Used in the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by neutralizing interleukin-17A (IL-17A), a key cytokine involved in inflammatory pathways, thereby reducing inflammation and disease symptoms. This antibody helps decrease skin lesions in moderate to severe plaque psoriasis and improves joint function and quality of life in patients with chronic inflammatory conditions. It is administered via subcutaneous injection and is part of a class of biologic therapies targeting specific components of the immune system.
Mechanism | - |
Appearance | - |
Longevity | - |
Strength | - |
Storage | - |
Shelf Life | - |
Allergen(s) | - |
Dosage (Range) | - |
Recommended Dosage | - |
Dosage (Per Day) | - |
Recommended Dosage (Per Day) | - |
Mix Method | - |
Heat Resistance | - |
Stable in pH range | - |
Solubility | - |
Product Types | - |
INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :